Text and Data Mining valid from 2018-10-17
First Online: 17 October 2018
: A.D. has received honoraria (as an advisory board member) from Bayer, Ignyta, Loxo Oncology, Pfizer, Roche/Genentech and TP Therapeutics, and research funding from Loxo Oncology. M.S. has received research funding from Daiichi Sankyo and Puma Biotechnology. E.C. declares no competing interests.